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Conclusion: This case cOntrol study suggests that the ACE delehon poly- 
morphism Is not a risk factor for the development of congestive heo~ failure, 
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Hyparcholeste~la is common after heart transplant and may be assocl. 
ated with the deser t  of transplant comnaw adew disease. The use of 
HMG.CoA redu~ase inhiblfom (HRI) in head transplant patients has demon- 
strafed eft~::acy in cholesterel Iowenng; however, there is concem of myOSdks 
and d ~ i s  with HRI in head ~ t  patients on cyctosponne. AS 
them are pa~ts  Mdt rehactow to ~ HRI thmapy, attention has lumed 
toward ato~astatm which ks a new HRI and ~rs  to he morn effective 
in cholesterol Iowenng and has reported ~ fowenng. Twenty-e~ght 
heart lransplant patients at an average of 42 months after heart tran~nt, 
refracton! to pmvmus HRI therapy, were ~ to ato~astatin t0 mg Ix) q 
d. There was a s~nificant reductmn after 3 months el therein, in total choies. 
terel (269 ± 48 to 220 ± 45 mg/cB, p = 0.01) and LDL cholesterol (145 ± 42 to 
121 ± 34 mg/dl, p ~ 0.0~). TnglycerKJe levels ten(leO to be lower (330 ± 163 
to 303 ± 199 moJdl), and them dKI not appear to be an appreciable change 
in HDL cholesterol (40 ~ 16 to 38 ± 13 mojdl). There were no sy.~Jiurss of 
myos~s and no d ~ i s  with creatine kinase levels unchanged at 3 
months (97 ± 61 to 99 ± 67 moJdl). 
Conclusion: The use of the new HRI. atorvastatin, appears safe and 
eftecbve in the short term for cholesterol Iowenng in heart transplant patients 
refraCton/tO other HRI. 
• Elfect Trabecular Bone Loss After of  Cslcitriol on 
Cardiac Transplantation 
C. Wemer, T Assure. S. Echller. B. Me~ser. C.E. Angermann. R. Gartner. 
W. Rambeck, K. Theisen, H.-U. Stempfle. Untversi~, of Munich. Germany 
Background: Accelerated bone loss is well recognized comp!¢atien affer 
cardiac transplantation (HTx) due to glucocort~'o~d and cyctospanne therapy. 
The puq:~se of this prospective randomized placebo-centre!led eubie-blind 
study was to investigate the effect of Calcitnol in the prevention of bone loss 
after cardiac transplantation. Basic therapy included calcium 1000 n~j dally 
and testosterone substitution in hypogonadal patients. 
Methods. 88 male patients (moan age: 49 ± 9 yrs.. 30 ± 30 months post 
HTx) and 16 female patients (mean age: 46 ± 12 yrs.; 35 ± 28 months pa-'~t 
HTx) were randomized to 0,25 l~g Catcitnol or Fiacebo. Bone mineral density 
(BMD, g/cm~; Z-score, %) was measured at the lumbar spine w~th DXA 
(Hotogic QDR 1000) at baseline and after 12 months. Vertebral fractures 
were assessed by X-rays. 
Calcnriol (1 ,~ 25(OH)2D3) Placebo 
Baseline 12 month Basel~e 12 month 
male patients BMD [g/cm 2] 0.941 0.960 0 C.24 0929 
Z-Score [%] 91 90 89 90 
Fractures 3 3 3 3 
female patients BMD [g;cm 2] 0862 0.907 0 886 0 865 
Z-Score [%] 92 96 93 94 
Fractures 1 1 1 t 
Results: Osteoporosis therapy including calcium and testosterone sub- 
stitution in patients with hypogcnadism improves bone mass after cardiac 
transplantation. Additional replacement doses of calcitriol demonstrates no 
signilicant extra benefit regarding bone mineral density and fracture rate. 
Calcitriot revealed only a mild beneficial effect in a subgroup of patients (n 
= 23) early after cardiac transplantation (4.2 :~ 2.3 months post HTx) with a 
Z-score increase of 3.4% vs. 0.3% in the placebo group. 
• Effect of Felodiplne Versul  Diuretics on Left 
Ventricular Hypert rophy In Orthotopic Hur t  
1Yansplant Recipients 
J. Schwlftor. T DeMarco, S Gtobits, H Sakuma, C Khnsk,, K Chatterje~, 
W.W Pa,mlny, CB Htggms University of C#ltfom~t San Frano.s¢o, San 
Fr~nosco~ 04, USA 
Background: Tho potential of antittylmrter~tves to ieduc~ regres~ of left 
vefllncular hypedrophy (LVH) deperK~ not only on blood pressure cont~0t 
but may bo modulated by neurehumoml adaptation and, in ~ heart 
transplant (OH'r) recq[~l~lta, it may lnterlem with ¢y¢lospanne (Co.k) me~. 
Purpose: Compare the effect of tl~ calcium ¢~lannel bk:)cker fefo¢l~l~ 
(Fell versus diumfCs (Oiu) on LVH, neurohumorsl responses and mterect~¢~ 
with CsA. 
Methods: Twenty4wo patmnta (2 rues after OHT) and 10 heafthy eubjecm 
(age/so~ matched) were e,,amined using Mill (1,5T, GE), LV ~me~,  LV 
masa (Simpaon'a rule) and ~mctmnal pammaters were calculated tram ~r~ 
gredient echo 8hen alia images (TRTE 25/'/ms), Men@or=at end,systol~c 
waJ! stress (Sea) was also ealcglatl~(I t.~ng dlCfOll¢ notch pressure (gk~rlved 
from camlid pulse tracings). In addition, plasma nompmephnn, el~nq~nn 
(EI~), m~J plasma mnin actwlty (PRA) were measured. During 4 mos Of treat- 
ment. for each patient average CsA level and average syslolic and dmstal¢ 
blood pressures (SBP, DBP) were obtained from repa~bve mea~uremems. 
At follow up, blood work and MRI were repeated (n : 19). 
Re~Julls: At besefine, LV mass in patients was i~creesed (p .  0.o02) and 
See was reduced (p -: O001 ) remus contmt~ i~dicafing excess hypertreohy. 
Heart rate, SBP, OBP, LV eiectKm ~act;'on, and Sea were mlar  fo~ both 
groups and ¢1~ not change dunng either ~ t  (2-way ANOVA), LV 
mass decreased dunng Fel treatment and in~,ed  with Diu (~ 'mg 
interaclmn: p < 0.0001. 2.way ANOVA) In the Diu group, changes in LV 
mass were posilwely conetatad wilh PRA and EI~ at follow-up and wdh 
average CsA levels (st~atmse regression). In the Fel group, cringes in LV 
mass were correlated with SBP. but not with PRA, Ep~ and CsA. 
Conclusions: In hearts wrth mlCeSS hypertrophy, Fel induced r e ~  of 
L'~H whereas Diu could not prm~nt a further increa~.e m m.~ss. This increase 
in mass was related to neurehumoral responses and CsA. The effect of CsA 
on LV mass may be alle~uated by FeL 
~ O r a i  Ganciclovlr  Pmphyiaxis  Redtmes 
Cylomegalovirus Disease During the First Year 
After ~a, - t  Transplantation 
G.M. Mullen. M.A Silver, C.E. Lawless, J. Mendaz, P.C. Barath, 
K Malinowska. B.A. Ptsanl, P.J. O'Keefe. JA  Robinson. V Yeldandi. Loyola 
Unmers~ of ChK:acjo, Heart Transplant P~."gram. Maywood. Illin~s, USA 
Cytomegalowrus Dmease (CMVD) leads to addito~al hospdatizations and 
morbidiW after heart transplantation. Our eadier CMVD prophylaxis r~men 
had been s~;quential intmveneous Ganc~clowr fer 14 days followed by 90 
days of oral Acyctovir (Group I) versus our current strategy of 14 days of 
intravenous Ganc~cto,,nr followed by 90 days of oral Ganoictovir (Group II). 
Group I iN = 77) Group 11 (N = 35) 
Sex 55 Male.r22 Female 27 Male/B Fen~le 
Age (yearsi 498 ~ 11 6 52. I ~ 12.8 
Serology NI CMVD All CMVD 
DOnor ~ 1Recipient • 24 14 (58%) 10 0 (0%) 
DOnor +,'Reop~nt 14 2 (14%) 6 2 (33%) 
DOnor /Recu~ent. 30 3(10%) 13 0(0%) 
DOnor /Reop~ent 9 I (11%l 6 0 ((Y%,) 
Total 20126 0%i 2 (5 9%l" 
One Year Patient Survival 66 (857%) 32 (91 4%)' 
Hospital Length o! Stay Index 0.948 0.248" 
"p. 0.01 
Conclusions: The combined sequential use of intravenous/oral Gano- 
clovir is more effective prophylaxis CMVD after cardiac trensplantabon than 
intravenous Ganctctovirloral Ac'yclovir, Hospital days due to CMVD are re- 
duced by intravenous/oral Ganciclovir significantly. 
~ Lipid Treatment and Survival After Heart 
Transplantation 
C.M. Ballantyne, B.C. Short, R.C. Bourge, H.J. Eisen, DP. Fishbein, 
S.H. Kubo, K.D. Lake, B. Badovancevic, D.O. Taylor. H.O. Venture. 
C.W. Yancy, Jr., J.B. Young. Baylor College of Medicine. Houston, TX. USA 
Background: The risks and benefits of lipid-lewenng therapy atler heart 
transplantation remain poorly defined, but one nonblinded, randomized, sin- 
gle-center trial has shown significant reduction in mortality with stalin ther- 
apy. 
